1. Home
  2. INDP vs FTHA Comparison

INDP vs FTHA Comparison

Compare INDP & FTHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$1.08

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

FTHA

Forefront Tech Holdings Acquisition Corp Class A Ordinary Shares

N/A

Current Price

$9.95

Market Cap

137.6M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
INDP
FTHA
Founded
2000
N/A
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
171.9M
137.6M
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
INDP
FTHA
Price
$1.08
$9.95
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
103.7K
34.4K
Earning Date
05-11-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$9.90
52 Week High
$8.57
$9.95

Technical Indicators

Market Signals
Indicator
INDP
FTHA
Relative Strength Index (RSI) 29.35 72.73
Support Level $0.92 $9.90
Resistance Level $2.95 N/A
Average True Range (ATR) 0.18 0.00
MACD -0.02 0.00
Stochastic Oscillator 5.83 100.00

Price Performance

Historical Comparison
INDP
FTHA

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About FTHA Forefront Tech Holdings Acquisition Corp Class A Ordinary Shares

Forefront Tech Holdings Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses.

Share on Social Networks: